FDA approves new treatment for rare genetic defect; Under pressure, Actelion plans first dividend;

@FierceBiotech: Inspire slashes 65 jobs, drops failed CF drug in restructuring. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Cambridge/Boston going and blowing as other biotech regions shrink. Cancer is a particularly hot field. Follow @JohnCFierce 

> The FDA has approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency. The FDA approved Corifact, which is made by German's CSL Behring, based on results of a clinical study of 14 people, including children. FDA release

> Actelion is proposing to hand out its first dividend as it looks for support among investors and tries to resist calls to put itself on the auction block. Story

> La Jolla, CA-based CalciMedica has dosed the first cohort in a Phase I clinical trial of CM2489, triggering an additional $6 million tranche of financing from all existing investors, which include Sanderling Ventures, SR One and Biogen Idec New Ventures. CalciMedica release

> The FDA has given Impax Laboratories final approval of the company's ANDA for its generic version of Adoxa. Impax release

And Finally... Northwestern University scientists have discovered that the loss of a certain gene, dubbed "twenty-four," messes up the rhythm of the common fruit fly's sleep-wake cycle, making it harder for the flies to awaken. Item